02.24.14
InVivo Therapeutics Holdings Corporation continues with its executive team selection with the appointment of Tomas R. Ulich, M.D., as chief scientific officer, effective February 24.
Ulich previously served as executive vice-president of research and development of ConjuChem Biotechnologies from 2006 to 2010. Prior to that, he served as senior vice president of research and development for Alnylam Pharmaceuticals. Before that he served at Amgen first as vice-president of preclinical development from 1993-2001 and then as vice-president of preclinical development and protein therapeutics.
Ulich has a BA from Dartmouth College in Hanover, N.H., and an M.D. from University of California, Los Angeles Medical School. His medical board certifications are from the American Board of Anatomic Pathology, the American Board of Clinical Pathology, and the American Board of Immunopathology.
Mark Perrin, InVivo’s CEO, said that Ulich would bring “a broad scientific background and expertise” to InVivo that would be invaluable to the company’s biomaterials portfolio.
Cambridge, Mass.-based InVivo Therapeutics is a biomaterials company that makes drug delivery technology with a focus on treatment of spinal cord injuries.
Ulich previously served as executive vice-president of research and development of ConjuChem Biotechnologies from 2006 to 2010. Prior to that, he served as senior vice president of research and development for Alnylam Pharmaceuticals. Before that he served at Amgen first as vice-president of preclinical development from 1993-2001 and then as vice-president of preclinical development and protein therapeutics.
Ulich has a BA from Dartmouth College in Hanover, N.H., and an M.D. from University of California, Los Angeles Medical School. His medical board certifications are from the American Board of Anatomic Pathology, the American Board of Clinical Pathology, and the American Board of Immunopathology.
Mark Perrin, InVivo’s CEO, said that Ulich would bring “a broad scientific background and expertise” to InVivo that would be invaluable to the company’s biomaterials portfolio.
Cambridge, Mass.-based InVivo Therapeutics is a biomaterials company that makes drug delivery technology with a focus on treatment of spinal cord injuries.